Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Dongjak-Gu, Korea, Republic of Clinical Trials

A listing of Dongjak-Gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (124) clinical trials

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of ponatinib over a range of 3 starting doses. Eligible participants must have chronic phase chronic myeloid leukemia (CP-CML) and have demonstrated resistance to treatment or have the T315I mutation.

Phase

0.45 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

0.45 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

0.45 miles

Learn More »

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 (NCT02833350)

This is a Phase II, multicenter, open-label extension study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active RA who have completed 12 weeks of study treatment in Study GA29350 (NCT02833350). Eligible participants from Study GA29350 who elect to participate will receive treatment ...

Phase

1.92 miles

Learn More »

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching placebo tablets will be ...

Phase

1.92 miles

Learn More »

Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).

Phase

1.92 miles

Learn More »

A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis

The purpose of this study is to evaluate efficacy and safety of YH23537 versus celebrex in patients with knee osteoarthritis.

Phase

1.92 miles

Learn More »

Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has ...

Phase

1.92 miles

Learn More »

A Study of Cobimetinib Plus Paclitaxel Cobimetinib Plus Atezolizumab Plus Paclitaxel or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants ...

Phase

1.92 miles

Learn More »

An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer

This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of JNJ-42756493 in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or ...

Phase

1.92 miles

Learn More »